Expanding precision oncology
With precision medicine, doctors tailor treatment to the molecular features of a person’s cancer. MSK scientists have identified hundreds of cancer-related mutations, proteins, and other traits, and pioneered new targeted therapies that take aim at them.
Pinpointing molecular drivers of cancer today
For decades, MSK has led progress in precision medicine, turning discoveries about cancer biology into therapies tailored to the characteristics of an individual’s disease.
- Researchers in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology examine the molecular features of tumors.
- MSK-IMPACT® detects 500-plus genes with cancer-related mutations and is used to match patients with targeted therapies.
- MSK-ACCESS® is a liquid biopsy test used to noninvasively diagnose cancer recurrence.
- MSK created the OncoKB® database to track which mutations are most clinically relevant for each kind of cancer.
To develop targeted drugs that give patients more tomorrows
With donor support, MSK can continue to push the field of precision medicine forward and change outcomes for more people around the world.
- Building on MSK-IMPACT, MSK is launching the Innovative Diagnostics Initiative, which brings MSK’s artificial intelligence and data science capabilities together with a new generation of clinical genomic tests.
- MSK-TARGET™, a part of this initiative, is an RNA sequencing test that offers even deeper insights into each person’s cancer. Recently approved by New York State for clinical validation, the test is being refined with data from thousands of patients — a step that could make it a future standard of care.
- MSK’s Early Drug Development Service is exclusively focused on early-stage clinical trials and gives patients opportunities to access new precision treatments.
Your generosity fuels breakthroughs that save lives
Progress made possible by the MSK Giving community
A milestone FDA approval
A clinical trial led by MSK resulted in the FDA approval for daraxonrasib (RasonqueTM) for pancreatic cancer. The drug that targets the KRAS mutation, which drives over 90% of pancreatic cancers.
Learn moreTranslating research into cures
Through a transformative $100 million gift, longtime donors Fiona and Stanley Druckenmiller are supporting promising translational research at MSK through the Fiona and Stanley Druckenmiller Presidential Innovation Fund.
Learn what donors can doA triple threat
MSK helped lead a clinical trial that showed a new three drug combination — which includes two targeted treatments — improved survival rates for people with ER-positive, HER2-negative breast cancer.
Read moreAccelerating progress
Donor support, including from the Tow Foundation, has fueled advances in an emerging type of precision medicine called theranostics. An MSK clinical trial led to expanded FDA approval of a targeted treatment for prostate cancer.
Read moreImproving outcomes for everyone
MSK researchers discovered that some patients are more likely than others to be matched to precision treatments based on their genetic ancestry. They’re now seeking to better understand these disparities to improve care for all.
Read more
Help us make the next big leap in precision oncology
The MSK Campaign: Leading Science. Changing Lives.
The MSK community is raising $6 billion by 2030 to accelerate advances across six key strategic initiatives. Learn more and join us in our mission of ending cancer for life.
Learn more about The MSK Campaign